TY - JOUR
T1 - Chemotherapy for recurrent salivary gland malignancies
T2 - Experience of the ENT Department of Turin University
AU - Airoldi, M.
AU - Brando, V.
AU - Giordano, C.
AU - Gabriele, P.
AU - Bussi, M.
AU - Cortesina, G.
PY - 1994
Y1 - 1994
N2 - Twenty-seven patients (17 males, 10 females; median age 59 years) with recurrent high-grade malignancies of major (22 cases) and minor (5 cases) salivary gland origin (10 adenoid cystic carcinomas, 9 adenocarcinomas, 4 poorly differentiated carcinomas, 1 mixed malignant tumor, 3 mucoepidermoid carcinomas) were treated by monochemotherapy - cisplatin (CDDP) in 8 cases, or adriamycin in 5 cases - or polychemotherapy - CDDP + epirubicin + 5-fluorouracil/cyclophosphamide in 9 cases or CDDP + 5-fluorouracil in 3 cases with mucoepidermoid carcinomas. In adenocarcinoma-like tumors, patients treated by polychemotherapy showed a better response (9.1% CR, 36.3% PR) than patients treated with monochemotherapy (no CR, 23% PR). Patients with local recurrence and adenocarcinoma exhibited a better response. Median response duration: 7.5 months after poly- and 4 after monochemotherapy. Median overall survival time was 8+ months (responders: 14+) in the polychemotherapy group and 5.5 (responders: 8) in the monochemotherapy group. In the 3 cases with mucoepidermoid carcinoma 1 patient achieved a PR (33.3%) and in 2 there was no change.
AB - Twenty-seven patients (17 males, 10 females; median age 59 years) with recurrent high-grade malignancies of major (22 cases) and minor (5 cases) salivary gland origin (10 adenoid cystic carcinomas, 9 adenocarcinomas, 4 poorly differentiated carcinomas, 1 mixed malignant tumor, 3 mucoepidermoid carcinomas) were treated by monochemotherapy - cisplatin (CDDP) in 8 cases, or adriamycin in 5 cases - or polychemotherapy - CDDP + epirubicin + 5-fluorouracil/cyclophosphamide in 9 cases or CDDP + 5-fluorouracil in 3 cases with mucoepidermoid carcinomas. In adenocarcinoma-like tumors, patients treated by polychemotherapy showed a better response (9.1% CR, 36.3% PR) than patients treated with monochemotherapy (no CR, 23% PR). Patients with local recurrence and adenocarcinoma exhibited a better response. Median response duration: 7.5 months after poly- and 4 after monochemotherapy. Median overall survival time was 8+ months (responders: 14+) in the polychemotherapy group and 5.5 (responders: 8) in the monochemotherapy group. In the 3 cases with mucoepidermoid carcinoma 1 patient achieved a PR (33.3%) and in 2 there was no change.
KW - Chemotherapy
KW - Recurrent disease
KW - Salivary carcinoma
UR - http://www.scopus.com/inward/record.url?scp=0027979597&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027979597&partnerID=8YFLogxK
M3 - Article
C2 - 8177583
AN - SCOPUS:0027979597
VL - 56
SP - 105
EP - 111
JO - ORL; journal for oto-rhino-laryngology and its related specialties
JF - ORL; journal for oto-rhino-laryngology and its related specialties
SN - 0301-1569
IS - 2
ER -